바이러스 벡터 제조 시장 : 바이러스 벡터 유형별, 적응증별, 용도별 - 세계 기회 분석 및 산업 예측(2023-2032년)

The viral vector production market is likely to experience a significant growth rate of 18.8% from 2023-2032 owing to increasing market demand from diagnostic and biotech sector - Allied Market Research

Viral vectors are tools used in gene therapy and vaccine development to deliver genetic material into target cells. They are derived from naturally occurring viruses that have been modified to remove their disease-causing ability while retaining their ability to efficiently enter cells and deliver the desired genetic material. Viral vectors are designed to carry and introduce therapeutic genes, such as missing or mutated genes, into the cells of patients.

They act as delivery vehicles, transporting the genetic material to the target cells where it may be expressed and produce the desired therapeutic effect. Several types of viruses are commonly used as viral vectors, including adenoviruses, adeno-associated viruses (AAV), lentiviruses, retroviruses, and others. Each type of viral vector has unique characteristics and is selected on the basis of factors such as the target cell type, the desired duration of gene expression and others.

The viral vector production process involves modifying the viral genome to remove disease-causing elements and inserting the therapeutic gene of interest. The modified viral vector is then produced in enormous quantities through cell culture or other manufacturing methods. Quality control measures are implemented to ensure the safety, potency, and purity of the viral vector product.

The increase in prevalence of genetic disorders worldwide is a significant driving force behind the growth of the viral vector production market. Genetic conditions such as muscular dystrophy, cystic fibrosis, and hemophilia impact a large number of individuals globally. For instance, National Hemophilia Foundation (2023) there are between 30,000 to 33,000 people who live with hemophilia in the U.S. Gene therapy offers promising potential for treatment of these disorders, providing the possibility of a cure or long-term treatment options.

Moreover, viral vectors play a crucial role in gene therapy as they act as carriers, delivering therapeutic genes into the targeted cells to correct the underlying genetic defects. The growth in awareness and knowledge about gene therapy among healthcare professionals and patients has contributed to the rise in demand for viral vector production.

In addition, the global incidence of cancer has been on the rise, with a substantial number of new cases being diagnosed annually. This alarming trend has spurred significant interest in innovative treatment modalities, and viral vectors have emerged as pivotal components in gene therapy strategies for combating cancer. These specialized vectors have the ability to transport therapeutic genes or induce modifications in target cells, thereby amplifying immune responses against cancerous cells.

In addition, viral vector platforms play a critical role in the advancement of oncolytic viral therapies, which utilize viruses to directly target and eradicate cancer cells. The increase in demand for effective cancer treatments serves as a driving force behind the growth in need for viral vectors and their production. Furthermore, the COVID-19 pandemic has led to a significant rise in viral vector production for vaccine development.

Viral vectors, such as adenoviruses, have been utilized as a platform for the development of COVID-19 vaccines. These vectors are engineered to carry the genetic material of the SARS-CoV-2 spike protein, stimulating an immune response in vaccinated individuals. The urgent need for effective vaccines to combat the global health crisis has accelerated the production of viral vectors and thus contributed significantly to the growth of the market.

However, the viral vector production market faces certain restraints that may impede its growth and development. One significant restraint is the excessive cost associated with viral vector production. The manufacturing process requires substantial upfront capital investment, specialized infrastructure, and skilled personnel. In addition, the use of expensive raw materials and quality control measures further escalates production costs. These high costs may limit accessibility and affordability of gene therapies and viral vector-based vaccines, hindering the wider adoption and market growth.

On the contrary, the viral vector production market presents significant opportunities for growth and innovation. The increase in adoption of gene therapies and viral vector-based vaccines, coupled with the expanding pipeline of promising candidates, fuels the demand for viral vectors. Advancements in vector engineering, manufacturing technologies, and process optimization create opportunities for more efficient and cost-effective production.

Furthermore, developing regions present significant opportunities for growth in the viral vector production market. Rise in healthcare expenditures, developing healthcare infrastructure, government initiatives and support for treatment of complex diseases is further anticipated to boost the demand for viral vector production in this region.

The global viral vector production market is segmented based on viral vector type, indication, application, end user, and region. On the basis of viral vector type, the market is categorized into adenoviral vectors, adeno-associated viral vectors, lentiviral vectors, retroviral, and other viral vectors. On the basis of indication, it is segregated into cancer, genetic disorders, infectious diseases, and other diseases. On the basis of application, it is bifurcated into gene therapy, and vaccinology.

On the basis of region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA). Major players that operate in the market include Andelyn Biosciences, Charles River Laboratories, Danaher Corporation., FinVector Oy, Lonza, Novartis AG, Oxford Biomedica plc, Takara Holdings Inc., Thermo Fisher Scientific Inc. and Avid Bioservices, Inc.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the viral vector production market analysis from 2022 to 2032 to identify the prevailing viral vector production market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the viral vector production market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global viral vector production market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Indication

• Cancer
• Genetic Disorders
• Infectious Diseases
• Other Diseases

By Application

• Gene Therapy
• Vaccinology

By Viral Vector Type

• Adenoviral Vectors
• Lentiviral Vectors
• Retroviral Vectors
• Adeno-Associated Viral Vectors
• Other Viral Vectors

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Andelyn Biosciences
• Avid Bioservices, Inc.
• Charles River Laboratories
• Danaher Corporation
• FinVector Oy
• Lonza
• Novartis AG
• Oxford Biomedica
• TAKARA HOLDINGS INC.
• Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research Methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Bargaining power of suppliers
  • 3.3.2. Bargaining power of buyers
  • 3.3.3. Threat of substitutes
  • 3.3.4. Threat of new entrants
  • 3.3.5. Intensity of rivalry
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Rise in prevalence of cancer, infectious diseases, and genetic disorders
    • 3.4.1.2. Increase in demand and awareness for gene therapy
    • 3.4.1.3. Surge in number of strategies adopted by market key players

• 3.4.2. Restraints
  • 3.4.2.1. High cost associated with viral vector production
  • 3.4.2.2. Regulatory Requirements for viral vector production

• 3.4.3. Opportunities
  • 3.4.3.1. Robust pipeline in gene therapy and viral vaccines

• 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: VIRAL VECTOR PRODUCTION MARKET, BY VIRAL VECTOR TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Adenoviral Vectors
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Lentiviral Vectors
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Retroviral Vectors
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country
• 4.5. Adeno-Associated Viral Vectors
  • 4.5.1. Key market trends, growth factors and opportunities
  • 4.5.2. Market size and forecast, by region
  • 4.5.3. Market share analysis by country
• 4.6. Other Viral Vectors
  • 4.6.1. Key market trends, growth factors and opportunities
  • 4.6.2. Market size and forecast, by region
  • 4.6.3. Market share analysis by country

CHAPTER 5: VIRAL VECTOR PRODUCTION MARKET, BY INDICATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Cancer
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Genetic Disorders
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Infectious Diseases
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country
• 5.5. Other Diseases
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by region
  • 5.5.3. Market share analysis by country

CHAPTER 6: VIRAL VECTOR PRODUCTION MARKET, BY APPLICATION

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Gene Therapy
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Vaccinology
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country

CHAPTER 7: VIRAL VECTOR PRODUCTION MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key trends and opportunities
  • 7.2.2. Market size and forecast, by Viral Vector Type
  • 7.2.3. Market size and forecast, by Indication
  • 7.2.4. Market size and forecast, by Application
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Key market trends, growth factors and opportunities
    • 7.2.5.1.2. Market size and forecast, by Viral Vector Type
    • 7.2.5.1.3. Market size and forecast, by Indication
    • 7.2.5.1.4. Market size and forecast, by Application
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Key market trends, growth factors and opportunities
    • 7.2.5.2.2. Market size and forecast, by Viral Vector Type
    • 7.2.5.2.3. Market size and forecast, by Indication
    • 7.2.5.2.4. Market size and forecast, by Application
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Key market trends, growth factors and opportunities
    • 7.2.5.3.2. Market size and forecast, by Viral Vector Type
    • 7.2.5.3.3. Market size and forecast, by Indication
    • 7.2.5.3.4. Market size and forecast, by Application
• 7.3. Europe
  • 7.3.1. Key trends and opportunities
  • 7.3.2. Market size and forecast, by Viral Vector Type
  • 7.3.3. Market size and forecast, by Indication
  • 7.3.4. Market size and forecast, by Application
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Key market trends, growth factors and opportunities
    • 7.3.5.1.2. Market size and forecast, by Viral Vector Type
    • 7.3.5.1.3. Market size and forecast, by Indication
    • 7.3.5.1.4. Market size and forecast, by Application
    • 7.3.5.2. France
    • 7.3.5.2.1. Key market trends, growth factors and opportunities
    • 7.3.5.2.2. Market size and forecast, by Viral Vector Type
    • 7.3.5.2.3. Market size and forecast, by Indication
    • 7.3.5.2.4. Market size and forecast, by Application
    • 7.3.5.3. UK
    • 7.3.5.3.1. Key market trends, growth factors and opportunities
    • 7.3.5.3.2. Market size and forecast, by Viral Vector Type
    • 7.3.5.3.3. Market size and forecast, by Indication
    • 7.3.5.3.4. Market size and forecast, by Application
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Key market trends, growth factors and opportunities
    • 7.3.5.4.2. Market size and forecast, by Viral Vector Type
    • 7.3.5.4.3. Market size and forecast, by Indication
    • 7.3.5.4.4. Market size and forecast, by Application
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Key market trends, growth factors and opportunities
    • 7.3.5.5.2. Market size and forecast, by Viral Vector Type
    • 7.3.5.5.3. Market size and forecast, by Indication
    • 7.3.5.5.4. Market size and forecast, by Application
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Key market trends, growth factors and opportunities
    • 7.3.5.6.2. Market size and forecast, by Viral Vector Type
    • 7.3.5.6.3. Market size and forecast, by Indication
    • 7.3.5.6.4. Market size and forecast, by Application
• 7.4. Asia-Pacific
  • 7.4.1. Key trends and opportunities
  • 7.4.2. Market size and forecast, by Viral Vector Type
  • 7.4.3. Market size and forecast, by Indication
  • 7.4.4. Market size and forecast, by Application
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Key market trends, growth factors and opportunities
    • 7.4.5.1.2. Market size and forecast, by Viral Vector Type
    • 7.4.5.1.3. Market size and forecast, by Indication
    • 7.4.5.1.4. Market size and forecast, by Application
    • 7.4.5.2. China
    • 7.4.5.2.1. Key market trends, growth factors and opportunities
    • 7.4.5.2.2. Market size and forecast, by Viral Vector Type
    • 7.4.5.2.3. Market size and forecast, by Indication
    • 7.4.5.2.4. Market size and forecast, by Application
    • 7.4.5.3. India
    • 7.4.5.3.1. Key market trends, growth factors and opportunities
    • 7.4.5.3.2. Market size and forecast, by Viral Vector Type
    • 7.4.5.3.3. Market size and forecast, by Indication
    • 7.4.5.3.4. Market size and forecast, by Application
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Key market trends, growth factors and opportunities
    • 7.4.5.4.2. Market size and forecast, by Viral Vector Type
    • 7.4.5.4.3. Market size and forecast, by Indication
    • 7.4.5.4.4. Market size and forecast, by Application
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Key market trends, growth factors and opportunities
    • 7.4.5.5.2. Market size and forecast, by Viral Vector Type
    • 7.4.5.5.3. Market size and forecast, by Indication
    • 7.4.5.5.4. Market size and forecast, by Application
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Key market trends, growth factors and opportunities
    • 7.4.5.6.2. Market size and forecast, by Viral Vector Type
    • 7.4.5.6.3. Market size and forecast, by Indication
    • 7.4.5.6.4. Market size and forecast, by Application
• 7.5. LAMEA
  • 7.5.1. Key trends and opportunities
  • 7.5.2. Market size and forecast, by Viral Vector Type
  • 7.5.3. Market size and forecast, by Indication
  • 7.5.4. Market size and forecast, by Application
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Key market trends, growth factors and opportunities
    • 7.5.5.1.2. Market size and forecast, by Viral Vector Type
    • 7.5.5.1.3. Market size and forecast, by Indication
    • 7.5.5.1.4. Market size and forecast, by Application
    • 7.5.5.2. Saudi Arabia
    • 7.5.5.2.1. Key market trends, growth factors and opportunities
    • 7.5.5.2.2. Market size and forecast, by Viral Vector Type
    • 7.5.5.2.3. Market size and forecast, by Indication
    • 7.5.5.2.4. Market size and forecast, by Application
    • 7.5.5.3. South Africa
    • 7.5.5.3.1. Key market trends, growth factors and opportunities
    • 7.5.5.3.2. Market size and forecast, by Viral Vector Type
    • 7.5.5.3.3. Market size and forecast, by Indication
    • 7.5.5.3.4. Market size and forecast, by Application
    • 7.5.5.4. Rest of LAMEA
    • 7.5.5.4.1. Key market trends, growth factors and opportunities
    • 7.5.5.4.2. Market size and forecast, by Viral Vector Type
    • 7.5.5.4.3. Market size and forecast, by Indication
    • 7.5.5.4.4. Market size and forecast, by Application

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. Andelyn Biosciences
  • 9.1.1. Company overview
  • 9.1.2. Key Executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Key strategic moves and developments
• 9.2. Charles River Laboratories
  • 9.2.1. Company overview
  • 9.2.2. Key Executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
  • 9.2.7. Key strategic moves and developments
• 9.3. Danaher Corporation
  • 9.3.1. Company overview
  • 9.3.2. Key Executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
  • 9.3.7. Key strategic moves and developments
• 9.4. FinVector Oy
  • 9.4.1. Company overview
  • 9.4.2. Key Executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Key strategic moves and developments
• 9.5. Lonza
  • 9.5.1. Company overview
  • 9.5.2. Key Executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
  • 9.5.7. Key strategic moves and developments
• 9.6. Oxford Biomedica
  • 9.6.1. Company overview
  • 9.6.2. Key Executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
• 9.7. TAKARA HOLDINGS INC.
  • 9.7.1. Company overview
  • 9.7.2. Key Executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
  • 9.7.7. Key strategic moves and developments
• 9.8. Thermo Fisher Scientific Inc.
  • 9.8.1. Company overview
  • 9.8.2. Key Executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
  • 9.8.7. Key strategic moves and developments
• 9.9. Novartis AG
  • 9.9.1. Company overview
  • 9.9.2. Key Executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
• 9.10. Avid Bioservices, Inc.
  • 9.10.1. Company overview
  • 9.10.2. Key Executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance
  • 9.10.7. Key strategic moves and developments